ATE329894T1 - Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament - Google Patents

Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament

Info

Publication number
ATE329894T1
ATE329894T1 AT01271349T AT01271349T ATE329894T1 AT E329894 T1 ATE329894 T1 AT E329894T1 AT 01271349 T AT01271349 T AT 01271349T AT 01271349 T AT01271349 T AT 01271349T AT E329894 T1 ATE329894 T1 AT E329894T1
Authority
AT
Austria
Prior art keywords
potentiation
ltp
synaptic transmission
cyclopropancyclus
medication
Prior art date
Application number
AT01271349T
Other languages
English (en)
Inventor
Tomoyuki Nishizaki
Akito Tanaka
Original Assignee
Tox Kk
Tomoyuki Nishizaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tox Kk, Tomoyuki Nishizaki filed Critical Tox Kk
Application granted granted Critical
Publication of ATE329894T1 publication Critical patent/ATE329894T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/04—Saturated compounds having a carboxyl group bound to a three or four-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/12—Saturated polycyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/28—Unsaturated compounds polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/35—Unsaturated compounds having unsaturation outside the rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01271349T 2000-12-19 2001-12-18 Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament ATE329894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR2157A AUPR215700A0 (en) 2000-12-19 2000-12-19 Carboxylic acid compound having cyclopropane ring

Publications (1)

Publication Number Publication Date
ATE329894T1 true ATE329894T1 (de) 2006-07-15

Family

ID=3826191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271349T ATE329894T1 (de) 2000-12-19 2001-12-18 Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament

Country Status (7)

Country Link
US (1) US7468389B2 (de)
EP (1) EP1343746B1 (de)
JP (1) JP4212894B2 (de)
AT (1) ATE329894T1 (de)
AU (1) AUPR215700A0 (de)
DE (1) DE60120752T2 (de)
WO (1) WO2002050013A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE08002964T1 (de) 2001-02-27 2009-09-03 Blanchette Rockefeller Neurosciences Institute Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
DE10254265A1 (de) * 2002-11-21 2004-06-03 Symrise Gmbh & Co. Kg 2-Heptylcyclopropyl-1-carbonsäure
TW201206425A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
CA2582270A1 (en) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease
KR20130122630A (ko) 2005-07-29 2013-11-07 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
JP5317405B2 (ja) * 2006-10-03 2013-10-16 知之 西崎 脳機能の改善剤及びそのスクリーニング方法
JP2008143819A (ja) * 2006-12-08 2008-06-26 Tomoyuki Nishizaki 酸化ストレス誘導細胞死の抑制剤
ES2548766T3 (es) * 2007-02-09 2015-10-20 Blanchette Rockefeller Neurosciences Institute Efectos terapéuticos de las briostatinas, briólogos y otras sustancias relacionadas en alteraciones de la memoria inducidas por trauma craneal y por lesiones cerebrales
JP5653917B2 (ja) 2008-07-28 2015-01-14 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2011529344A (ja) * 2008-07-28 2011-12-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の刺激誘発ゲノムプロフィールマーカー
JP5455396B2 (ja) * 2009-02-27 2014-03-26 知之 西崎 プロテインホスファターゼ−１阻害剤
CA2776501C (en) * 2009-10-02 2022-04-19 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of alzheimer's disease
US20110212474A1 (en) * 2009-10-02 2011-09-01 Blanchette Rockefeller Neurosciences Institute Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
EP2641891B1 (de) * 2010-11-16 2019-07-03 Nishizaki Bioinformation Research Institute PKC-epsilon AKTIVATOR
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
JP6316272B2 (ja) 2013-02-15 2018-04-25 株式会社 西崎創薬研究所 シクロプロパン環を有する不飽和脂肪酸誘導体を含むリン脂質化合物
WO2014129598A1 (ja) * 2013-02-22 2014-08-28 株式会社西崎創薬研究所 τタンパク質リン酸化抑制剤
WO2014163178A1 (ja) * 2013-04-04 2014-10-09 株式会社西崎創薬研究所 エラスチン合成・再生促進剤
EP2997967A4 (de) 2013-05-17 2017-01-04 Nishizaki Bioinformation Research Institute Zellmembrantransportpromotor für selektive 5-ht1a-serotoninrezeptoren
WO2014196621A1 (ja) 2013-06-07 2014-12-11 Ｋｔｎバイオテック株式会社 抗癌剤
US9889104B2 (en) 2014-01-07 2018-02-13 Nishizaki Bioinformation Research Institute Agent for treating diabetes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL45320A (en) * 1974-07-22 1980-03-31 Nechama S Kosower Cyclopropane fatty acids alkoxyalkyl esters and their use as membrane mobility agents in plant and animal cells
JPS5795937A (en) * 1980-12-08 1982-06-15 Ono Pharmaceut Co Ltd Leucotriene a analogous compound, its preparation, and leucotriene biosynthetic inhibitor containing said compound as active constituent
US4442099A (en) * 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
JPS58194836A (ja) * 1982-05-11 1983-11-12 Sankyo Co Ltd ５，６−メタノ−ロイコトリエンａ４誘導体
US4562006A (en) * 1984-01-11 1985-12-31 Warner-Lambert Company Cycloheptadiene derivatives
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9514448D0 (en) * 1995-07-14 1995-09-13 Iaf Biochem Int Novel heterocyclic NMDA-receptor antagonists
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6169103B1 (en) * 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
JPH11299285A (ja) * 1998-04-16 1999-10-29 Fanuc Ltd サーボアンプ
NZ525513A (en) * 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
ATE366259T1 (de) * 1999-03-04 2007-07-15 Praecis Pharm Inc Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
US6887898B1 (en) * 1999-10-22 2005-05-03 Darrick S. H. L. Kim Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease

Also Published As

Publication number Publication date
US7468389B2 (en) 2008-12-23
DE60120752D1 (de) 2006-07-27
AUPR215700A0 (en) 2001-01-25
EP1343746A1 (de) 2003-09-17
US20050075393A1 (en) 2005-04-07
WO2002050013A1 (en) 2002-06-27
JP4212894B2 (ja) 2009-01-21
JP2004516277A (ja) 2004-06-03
DE60120752T2 (de) 2006-10-12
EP1343746B1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
ATE329894T1 (de) Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament
ES2101421T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
ES2102132T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
ATE167476T1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
ATE175201T1 (de) Mono-n-substituierte 1,4,7,10- tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE69613365T2 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
ATE71372T1 (de) Benzothiazol-derivat und es als aktiven bestandteil enthaltendes antirheumatisches mittel.
EP1312601A4 (de) Carbonsäurederivate, verfahren zu deren herstellung und medikamente, die diese als wirkstoff enthalten
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
EP0633254A4 (de) Neue isoxazolderivate und ihre salze.
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
DE69518159D1 (de) Mittel zur vorsorge und heilung von typ i allergischen krankheiten
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
EP0446921A3 (en) Optically active alkylene-dioxybenzene derivatives and their use in therapy
FI923662A (fi) Terapeutiska medel
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
AU2001225143A1 (en) Tetramic acid derivatives for use in medicine and food technology
DK1633374T3 (da) Sammensætning af alkandicarboxylsyrer og et farmaceutisk aktivt stof
ATE66145T1 (de) Pharmazeutische verwendung aromatischer thioaether.
TH21523A (th) 2,8-ไตซับสทิทิวเทคควิราโซลิโนน
IT1229846B (it) Esteri di catecolammine.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties